FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint
FDA approves Erleada (apalutamide), first treatment for non-metastatic, castration-resistant prostate cancer
Source: Food and Drug Administration - Category: American Health Source Type: news
More News: American Health | Cancer | Cancer & Oncology | Clinical Trials | Food and Drug Administration (FDA) | Prostate Cancer